Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

FDA Oncology Update

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer

Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation

Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma

Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma

Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer

Rylaze Received FDA Approval of a New Dosing Regimen

Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma

Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations

Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

Page 1 of 21
Results 1 - 10 of 209